Prostate cancer is the second leading cause of cancer death in men. The cancer stems from a malignant tumor that originates in the prostate gland. As the tumor grows it can spread to other areas of the body, including nearby lymph nodes, bones and organs. In the past 20 years, five-year survival rates for all stages of prostate cancer combined have increased from 67% to 99% due to advances in medical technology and detection equipment. There are approximately 1.30 million prostate biopsies performed in the U.S. each year. Envisioneering has developed a scanning technology that improves accuracy and outcomes of…
Author: Global Cancer Consortium
As the name implies, Concierge MedTravel is a medical travel service. Concierge arranges appointments, international travel, transportation, hotel and hospital accommodations for clients. The company caters to men in need of a minimally invasive prostate cancer treatment, specifically an alternative prostate cancer treatment known as Ablatherm High Intensity Focused Ultrasound (HIFU) that is not available in the U.S. Concierge sends customers to St. Josef Hospital, a medical center with a team of 20 urological medical specialists, located at the University of Regensburg in Germany. Concierge will coordinate with your local physician, who will continue to provide care once treatment is…
You’ve got to hand it to the PR folks at Aethlon Medical. Every time I come across one of the company’s press releases I think I’ve stumbled upon the holy grail of medicine – the solution from which all cures will come. The company’s Hemopurifier separates and captures infectious viruses and toxins from circulating blood. The device, which resembles a modified kidney dialysis cartridge, is designed to exploit the pre-existing global infrastructure of dialysis machines present in hospitals and clinics. With the Hemopurifier, the company has: Studied the effectiveness of HIV treatment Reversed immune suppression in cancer patients Been developing…
This week, the OneMedPlace team is down in Orlando attending the American Urological Association’s annual meeting. We’ll be capturing some great video footage from the floor which we’ll be sharing later this month. While we’ve got Urology on the brain, I thought I’d weigh in on the recently announced upgrade to the Urologix enlarged prostate treatment catheter, CTC Advance. It’ll be years (with any luck) before I need worry about my prostate, but working in the device space, I’m cognizant of what lays ahead. By the time I’m 60, chances are good that I’ll experience symptoms of an enlarged prostate;…
Safeguard Scientifics is a holding company that invests in growth-stage life sciences and technology. In addition to capital, Safeguard provides strategic, operational and management resources to its portfolio companies. As a public company (NYSE: SFE), Safeguard is not subject to the limits of the three-to-seven-year fund raising cycles found in venture capital or buyout firms. This allows Safeguard to focus on growing its portfolio companies at an appropriate pace. Safeguard has investments in ten technology and ten life science-focused companies; the latter includes the following diagnostics, medical device and specialty pharmaceutical firms: Advanced BioHealing Alverix Avid Radiopharmaceuticals Cellumen Clarient NuPathe…
Myriad Genetic Laboratories develops and markets proprietary predictive and personalized medicine products. This includes the poorly branded BRACAnalysis, to assess a woman’s risk of developing breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes. The test is reimbursed by most insurance carriers and is recommended for women with a family history of breast or ovarian cancers. The company’s first advertising campaign began in 2002 and lasted five months. Airing in Atlanta and Denver, Myriad intended to raise awareness of cancer prevention through television, radio and print media. The direct-to-consumer (DTC) campaign stirred up some…
ImmunoVaccine Technologies (IVT) is a private biotechnology company developing therapeutic cancer and infectious disease vaccines. VacciMax technology is based on a novel approach to the use of liposomes. While liposomes typically contribute only marginally to the production of an immune response, IVT has discovered that liposomes stabilized by VacciMax technology significantly enhance antibody production. The company believes VacciMax will have the greatest impact in therapeutic cancer applications by stimulating earlier, more powerful, and longer lasting immune responses. An End to Three Dose Vaccine Regimens? In a variety of human infectious disease and cancer models, a three dose regime of vaccine…
Five cancer cells were injected subcutaneously into the dorsal region near the thigh of mouse. Tumor growth is monitored weekly by an IVIS Spectrum. The tumor was visible 28 days post implantation; Bioluminescent signal could be detected in the animal long before it could be measured with a caliper. By tagging a tumor with the gene for luciferase, the same gene that allows a firefly to glow, it can produce light that can be monitored in vivo using imaging systems. In vivo imaging provides researchers with the ability to monitor tumor growth and behaviors in living animals. Visualizing and tracking…